Origenis GmbH has identified cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, obesity, diabetes, viral infections, cardiovascular disorders and inflammatory disorders.
Eli Lilly & Co. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of atopic dermatitis and rheumatoid arthritis.
Wista Laboratories Ltd. has disclosed thiazole-containing compounds acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of corticobasal syndrome, Alzheimer’s disease, Down syndrome and more.
Biointervene Inc. has described adenosine analogues acting as adenosine A3 receptor (ADORA3) agonists reported to be useful for the treatment of mild cognitive impairment, diabetic neuropathy, irritable bowel syndrome, neurodegeneration, ototoxicity, neuropathic pain, chemotherapy-induced peripheral neuropathy and spinocerebellar ataxia, among others.
Shionogi & Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity and diabetes type 2.
Osaka University has identified radiolabeled tyrosine derivatives targeting large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) reported to be useful for the treatment of cancer.
Neurocrine Biosciences Inc. has synthesized vesicular monoamine transporter 2 (VMAT2) inhibitors reported to be useful for the treatment of hyperkinesia and psychosis.
University of California Oakland has described potassium channel subfamily K member 2 (TREK-1; KCNK2) and/or potassium channel subfamily K member 10 (TREK2; KCNK10) activators reported to be useful for the treatment of Caisson disease (decompression sickness), depression, headache, pulmonary hypertension, insomnia, chronic pain, lung and neuronal Injury.
RSS